Scientific
Evidence review, mechanisms, literature, methods, and publication integrity.
Institutional architecture
Company
A pharmaceutical company in formation designed around transparent evidence, interdisciplinary science, and disciplined governance.
Company position
Serious science before permanent titles.
trūth is a future C Corporation assembling the scientific, clinical, regulatory, ethical, operational, and financial structure required to develop Belcopa and NovusClarus responsibly.
Leadership appointments pending
Permanent executive roles will follow independent scientific and regulatory review, formation planning, and definition of the company’s development obligations.
Operating model
Functions before personalities.
The organization is represented through accountable scientific and operational functions rather than invented leadership biographies.
Clinical
Indication, endpoints, investigator network, participant safety, and trial conduct.
Regulatory
Product classification, FDA strategy, DEA requirements, submissions, and compliance.
Ethics
Consent, privacy, vulnerability, conflicts, community impact, and independent oversight.
Operations
Finance, legal, CMC, quality, partnerships, data systems, and program management.
Digital architecture
Headless system. Human accountability.
Content, evidence classifications, disclosures, program status, documents, permissions, and audit history are managed independently from the public interface.
Public Science Layer
Product pages, evidence records, development status, references, disclosures, and updates.
Partner Layer
Expressions of interest, advisory applications, investigator engagement, and institutional communication.
Protected Data Room
Source records, protocols, de-identified datasets, regulatory materials, diligence, and controlled sharing.
Governance build
Open leadership and advisory roles.
The company is seeking domain experts who understand that a strong advisory relationship includes the freedom to reject a favored hypothesis.
Medical & Clinical
Neurology, multiple sclerosis, pain, psychiatry, pharmacology, and clinical development.
Open opportunityRegulatory & CMC
FDA strategy, controlled substances, formulation, GMP, toxicology, and quality systems.
Open opportunityEthics & Anthropology
Research ethics, informed consent, patient agency, context, ritual, and medical anthropology.
Open opportunity